Nuzenio

Encouraging Darlifarnib Combination

Encouraging Darlifarnib Combination news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Adanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC - Urology TimesUrology Times · Tue, 28 Jul 2026 07:00:00 GMTAnalyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC - TipRanksTipRanks · Mon, 27 Jul 2026 18:51:46 GMTCharles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data - TipRanksTipRanks · Mon, 27 Jul 2026 18:51:46 GMTDarlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMTKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 - markets.businessinsider.commarkets.businessinsider.com · Mon, 27 Jul 2026 07:00:00 GMTKura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTKura's Drug Combo Shows 13-Month Median Without Progression - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Tue, 28 Jul 2026 07:00:00 GMTAdanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC - Urology Times
Mon, 27 Jul 2026 18:51:46 GMTAnalyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC - TipRanks
Mon, 27 Jul 2026 18:51:46 GMTCharles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data - TipRanks
Mon, 27 Jul 2026 15:10:16 GMTDarlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted Oncology
Mon, 27 Jul 2026 07:00:00 GMTKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 - markets.businessinsider.com
Mon, 27 Jul 2026 07:00:00 GMTKura Oncology Reports 50% Response Rate in RCC Combination Study - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Encouraging Darlifarnib Combination.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.